

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 9

Date: 26/03/2024

Location: Virtual (Zoom)

Minutes: Final

Committee members present:		
Alison Tedstone (Chair)		(Present for notes 1 – 6)
Nicola Peel (Topic adviser)		(Present for notes 1 – 6)
Alison Ahmed		(Present for notes 1 – 6)
Irene Baker		(Present for notes 1 – 6)
Sherwin Criseno		(Present for notes 1 – 6)
Elaine Dennison		(Present for notes 1 – 6)
Paul Hamilton		(Present for notes 1 – 6)
Karen Knapp		(Present for notes 1 – 6)
Kay Morgan		(Present for notes 1 – 6)
Rachel Muir		(Present for notes 1 – 6)
Nicholas Pipkin		(Present for notes 1 – 6)
Stuart Ralston		(Present for notes 4 – 6)
Karen Whitehead		(Present for notes 1 – 6)

In attendance:		
Rebecca Boucher	Editor	(Present for notes 1 – 6)
Annette Chalker	Systematic Reviewer	(Present for notes 1 – 6)
Angela Cooper	Systematic Reviewer	(Present for notes 1 – 6)
Rachel Connolly	Systematic Reviewer	(Present for notes 1 – 6)
Sarah Glover	Information Specialist	(Present for notes 1 – 6)
Amber Hernaman	Project Manager	(Present for notes 1 – 6)
Bernard Higgins	Clinical advisor	(Present for notes 1 – 6)
Kate Lovibond	Senior Health Economist	(Present for notes 1 – 6)
Suzie Panek	Resource Impact Lead	(Present for notes 1 – 6)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 6)
Claire Sloan	Health Economist	(Present for notes 1 – 6)
Nick Staples	Guideline	(Present for notes 1 – 6)

	Commissioning Manager	
--	--------------------------	--

Apologies:

Iain Macleod	Committee member
Rajesh Varma	Committee member
Muksitur Rahman	Health Economist
Julie Neilson	Senior Systematic Reviewer

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the ninth Osteoporosis guideline committee. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- Timing and duration of bisphosphonates evidence review
- Health economic model

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was timing and duration of bisphosphonates.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting. Declarations of interest are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Prof Karen Knapp	Diagnostic Radiographer	Part funded to attend the European Congress of Radiology in Vienna Feb / Mar 2024 (conference fees plus partial expenses) as an invited speaker for a talk on the complex interventions	Direct financial interest	Declare and participate.

		framework.		
Prof Karen Knapp	Diagnostic Radiographer	Book chapter on Person-centred care in DXA and secondary fracture prevention – co-author with Jill Griffin in Person-centred care in Radiology: International Perspectives on High Quality Care CRS Press	Direct non-financial professional and personal interests	Declare and participate.
Prof Karen Knapp	Diagnostic Radiographer	Co-Editor for Person-centred care in Radiology: International Perspectives on High Quality Care S Chau, E Hyde, K Knapp, C Hayre CRS Press	Direct financial interest	Declare and participate.
3. Minutes of last meeting				
Agreed.				
4. Timing and duration of bisphosphonates evidence review				
Annette Chalker presented the clinical evidence to the committee and Carlos Sharpin and Amber Hernaman made live edits to the recommendations.				
5. Health Economics				
Claire Sloan presented the health economic model to the committee and Kate Lovibond updated the committee with the status on Zoledronic Acid.				
6. AOB				
Carlos Sharpin raised the exercise review with the committee and Alison Tedstone discussed the possibility of having an in-person meeting.				

Date of next meeting: 30/04/2024

Location of next meeting: Zoom